French pharmaceutical company Sanofi (NASDAQ: SNY) has announced that its Phase III trial for rilzabrutinib, a potential best-in-class BTK inhibitor, has successfully met its primary endpoint of durable platelet response in patients with immune thrombocytopenia (ITP). The trial also produced positive results in key secondary endpoints and did not raise any new safety concerns for the orphan drug.
Rilzabrutinib is currently under fast-track review for the treatment of ITP by the U.S. regulatory authorities.- Flcube.com
